Bill Gates invests in computational drug discovery firm

- Last updated on GMT

Related tags: Chemistry

Nimbus Discovery has signed up Microsoft CEO Bill Gates and Richard Friesner, co-founder of chemical simulation software developer Schrodinger, as investors.

Massachusetts-based Nimbus uses computational chemistry to identify drug candidates for ‘difficult-to-treat’ diseases including cancers, inflammatory disorders and metabolic conditions.

Nimbus announced the news as part of an extension to its first financing round, explaining that it “follows a $10m investment by Bill Gates in Schrödinger to accelerate R&D efforts​.”

Chairman Bruce Booth explained that: “Their investment recognizes the unique opportunity Nimbus has to leverage Schrödinger’s 20-year technology investment with a virtually-integrated, globally distributed R&D approach​.”

Nimbus established an exclusive partnership with Schrodinger in 2010, under which it has exclusive rights to use of customized software packages and support services.

Related topics: Preclinical Research, Preclinical

Related news

Related product

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q² Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Related suppliers

Follow us

Products

View more

Webinars